...
首页> 外文期刊>European journal of gastroenterology and hepatology >Epidemiology of drug-induced liver injury in China: A systematic analysis of the Chinese literature including 21 789 patients
【24h】

Epidemiology of drug-induced liver injury in China: A systematic analysis of the Chinese literature including 21 789 patients

机译:中国药物性肝损伤的流行病学:对包括21 789例患者的中国文献的系统分析

获取原文
获取原文并翻译 | 示例

摘要

Background: The epidemiology of drug-induced liver injury (DILI) in China has rarely been studied before. The aim of the present study was to determine the etiology of DILI in a Chinese population by reporting a systematic analysis of the Chinese literature published from 1994 to 2011. Methods: A comprehensive database search of the Chinese literature was performed to obtain all the relevant studies. The data, including the drug names and patients' sex, age, clinical classification, and prognosis, were collected and analyzed. Results: In this research, we found 279 studies including 24 112 patients. There were 265 studies that reported the sex of 21 789 patients, 11 787 men and 10 002 women. The therapeutics included (but were not limited to) tuberculostatics, complementary and alternative medicines (CAMs), antibiotics, NSAIDs, antineoplastics, central nervous system agents, antithyroid drugs, and immunomodulators. Of these drugs, tuberculostatics and CAMs were the most common etiologies of DILI in China. Conclusion: DILI in China has a different etiology from that in Europe and USA. NSAIDs, which are the most common causes of DILI in western populations, are uncommon in China. Therefore, government, physicians, and patients should pay more attention to these drugs in DILI.
机译:背景:中国对药物性肝损伤(DILI)的流行病学研究很少。本研究的目的是通过报告对1994年至2011年间发表的中国文献的系统分析来确定中国人群中DILI的病因。方法:对中国文献进行全面的数据库检索,以获取所有相关研究。 。收集并分析包括药物名称和患者性别,年龄,临床分类和预后的数据。结果:在这项研究中,我们发现了279项研究,包括24 112例患者。有265项研究报告了21789例患者的性别,其中11787例男性和10002例女性。治疗药物包括(但不限于)结核抑制剂,补充和替代药物(CAM),抗生素,NSAID,抗肿​​瘤药,中枢神经系统药,抗甲状腺药和免疫调节剂。在这些药物中,抗结核药和CAM是中国DILI的最常见病因。结论:中国的DILI与欧洲和美国的病因不同。 NSAID是西方人群中DILI的最常见病因,在中国并不常见。因此,政府,医师和患者在DILI中应更加注意这些药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号